Immune microenvironment in breast cancer

  • L. A. Sivak National Cancer Institute
  • A. N. Grabovyj National Cancer Institute
  • N. O. Verovkina National Cancer Institute
  • S. A. Lyalkin National Cancer Institute
  • N. M. Majdanevych National Cancer Institute
  • A. V. Askolskyy National Cancer Institute
  • M. Yu. Klimanov National Cancer Institute
Keywords: breast cancer, tumor microenvirolement, chemotherapy, anti-HER2 therapy

Abstract

Traditionally, breast cancer has not been considered as a typical immunogenic tumor type. Nevertheless, it is well known that breast cancer is a heterogeneous mixture of different molecular subtypes and infiltration of tumor tissue by immunocompetent cells is associated with response to chemotherapy and survival in a certain molecular subtypes of breast cancer. Analysis of works of various research groups suggests that, immune markers, such as the presence of CD8 + lymphocytes, T regulatory cells in the tumor, as well as the ratio of CD8/CD4T should be used to stratify risk groups with prognostically unfavorable types of breast cancer as well as use as a factor in predicting the effectiveness of anti-HER2 therapy and chemotherapy for triple negative and HER2-overexpressing breast cancer subtypes.

Downloads

Download data is not yet available.

References

1. Заридзе Д. Г. Канцерогенез. – М.: Медицина, 2004. – 576 с.

2. Осинский С. П. Микроокружение опухолевых клеток и опухолевая прогрессия // Здоров’я України. – 2012. – № 12. – С. 34–35.

3. Ali1 H. R., Provenzano E., Dawson S.-J. еt al. Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients // Ann. Oncol. – 2014. – Vol. 25, N 8. – P. 1536–1543.

4. Andre F., Dieci M., Dubsky P. et al. Molecular Pathways: Involvement of Immune Pathways in theTherapeutic Response and Outcome in Breast Cancer // Clin. Cancer Res. – 2012. – Vol. 19, N 1. – P. 28–33.

5. Coulie P., van den Eynde B., van der Bruggen P. & Boon T. Tumor antigens recognized by T lymphocytes: at the core of cancer immunotherapy // Nature Reviews Oncology. – 2014. – Vol. 14, N 2. – P. 135–146.

6. Criscitiello Carmen. Tumor-Associated Antigens in Breast Cancer // Breast Care. – 2012. – N 7. – P. 262–266.

7. De Nardo D., Brennan D., Rexhepaj E. et al. Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy // Cancer Discovery. – 2011. – Т 1. – Р. 54–67.

8. Denkert C., Darb-Esfahani S., Loibl S. et al. Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy // Semin Immunopathol. – 2011. – Vol. 33. – P. 341–351.

9. Denkert C., Loibl S., Noske A. et al. Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer // J. Clin. Oncol. – 2010. – Vol. 28, N 1. – P. 105–113.

10. Hanahan D., Weinberg R. A. The hallmarks of cancer // Cell. – 2000. – Vol. 100. – P. 57–70.

11. Hua Fang, Yves A. De Clerck. Targeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials // Cancer Res. – 2013. – Vol. 73, N 16. – P. 4965–4977.

12. Loi Sh., Sirtaine N., Piette F. et al. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 // J. Clin. Oncol. – 2013. – Vol. 31, N 7. – P. 860–867.

13. Loi1 S., Michiels S., Salgado R. et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial // Ann. Oncol. – 2014. – Vol. 25, N 8. – P. 1544–1550.

14. Mahmoud S. M., Paish E. C., Powe D. G. et al. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer // Breast. Cancer Res. Treat. – 2011. – Vol.127. – P. 99–108.

15. Mahmoud Sh., Paish E., Powe D. G. et al. Tumor-Infiltrating CD8 Lymphocytes Predict Clinical Outcome in Breast Cancer // J. Clin. Oncol. – Vol. 29, N 15. – P. 1949–1955.

16. Ming-Ju Tsai, Wei-An Chang, Po-Lin Kuo. Tumor Microenvironment: A New Treatment Target for Cancer // ISRN Biochemistry. – 2014. – Article ID 351959.

17. Park S., Jiang Z., Mortenson E. D. et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity // Cancer Cell. – 2010. – Vol. 18. – P. 160–170.

18. Ruffell B., Au A., Rugo H. S. et al. Leukocyte composition of human breast cancer // Proc. Natl. Acad. Sci. USA. – 2012. – Vol. 109. – P. 2796–2801.

19. Shiao S., Ganesan A., Rugo H., & Coussens L. Immune microenvironments in solid tumors: new targets for therapy // Genes & Development. – 2011. – Vol. 25. – P. 2559–2572.

20. Shigeoka M., Urakawa N., Nakamura T. et al. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma // Cancer Sci. – 2013. – Vol. 104, N 8. – P. 1112–1119.

21. Stagg John & Allard Bertrand. Immunotherapeutic approaches in triple negative breast cancer: latest research and clinical prospects // Ther Adv. Med. Oncol. – 2013. – Vol. 5, N 3. – P. 169–181.

22. Zitvogel L., Tesniere A., Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion // Nat. Rev. Immunol. – 2006. – N 6. – P. 715–727.

Abstract views: 78
PDF Downloads: 11
Published
2017-03-30
How to Cite
Sivak, L. A., Grabovyj, A. N., Verovkina, N. O., Lyalkin, S. A., Majdanevych, N. M., Askolskyy, A. V., & Klimanov, M. Y. (2017). Immune microenvironment in breast cancer. Likars’ka Sprava, (1-2), 83-88. Retrieved from https://liksprava.com/index.php/journal/article/view/19
Section
Original intestigations